Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer



Status:Completed
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/7/2015
Start Date:September 2010
End Date:December 2013
Contact:Sarah Fanizzi
Email:CancerResearch@Swedish.org
Phone:(206) 215-3086

Use our guide to learn which trials are right for you!

Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer

The purpose of the study is to determine the optimal, lowest dose of radioactive tracer
required for Positron Emission Mammography (PEM), and the accuracy and reliability of PEM in
pre-surgical evaluations for patients with newly diagnosed breast cancer anticipating
breast-conserving surgery but identified to have a second unsuspected breast cancer by MRI.

The purpose of this research in Phase 1 is to determine the lowest dose of radionuclide
18F-FDG that can be used in the Diagnostic use of Positron Emission Mammography for the
diagnosis of multifocal breast cancer in patients wishing to have Breast Conservation
Surgery for newly diagnosed breast cancer. Low dose injections (radioactive counts) of
18F-FDG will be compared to the equivalent radioactive counts for the standard higher dose
10 millicuries used in standard PEM studies in current clinical practice. Images will be
post processed by computer aided software and will be placed in two categories: Low dose
group, and higher dose group. Images will be randomly blinded to readers to assess the
ability to see positive lesions that warrant further biopsy or to include in current
surgical planning prior to breast conservation surgery or mastectomy. Images will be
assessed for ability to see the PEM positive lesions on the lower dose images and this will
be compared to the ability to see the PEM positive lesions on the standard higher dose
images. Each of three breast cancer categories will be assessed Infiltrating Ductal
Carcinoma, Lobular infiltrating Carcinoma, and Ductal Carcinoma Insitu. Phase 1 will have 30
patients.

The purpose of the research in Phase 2 is to use the lowest dose identified in Phase 1 for
imaging primary breast cancer patients who have been identified by breast MRI to have an
unsuspected second lesion of the breast not expected from Mammography or Ultrasound that
requires biopsy for diagnosis prior to the biopsy to compare the reliability of PEM and MRI
for identifying breast cancer at the 2nd site. Parameters assessed will include standard
statistical analysis for sensitivity, specificity, positive predictive value and negative
predictive value for MRI and PEM imaging with the new lower radionuclide dose selected by
Phase 1. Phase 2 will have 100 patients.

Inclusion Criteria:

- Must be 18 years of age or older

- Newly diagnosed primary breast cancer

- Must have a breast or breast/chest MRI ordered as part of standard of care

- Must meet one or more of the following in Part 1:

- T1 carcinoma of the breast appropriate for breast conserving surgery diagnosis
established by core biopsy

- Tis (ductal carcinoma in situ) carcinoma > 2 cm diameter

- Invasive lobular carcinoma of the breast

- Must meet the following in Part 2:

- Known invasive or in situ primary breast cancer identified on pre-surgical
breast MRI to have an unsuspected 2nd lesion recommended for biopsy and biopsy
has not yet been performed

Exclusion Criteria:

- Known diabetes mellitus
We found this trial at
2
sites
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Seattle, Washington 98104
?
mi
from
Seattle, WA
Click here to add this to my saved trials